FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average burden											
hours per response:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) C/O SER	vid S.	APEUTICS, INC	(Middle)		2. Issuer Name and Ticker or Trading Symbol Seres Therapeutics, Inc. [MCRB] 3. Date of Earliest Transaction (Month/Day/Year) 02/03/2023								(Ch	telationship of Reporting Person(s) to Issuer eck all applicable) Director 10% Owner Officer (give title Other (specify below) See Remarks				
(Street) CAMBR (City)	IDGE M	A	02139 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable lee) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction 2. Deemed 3. 4. Securities Acquired (A) or 5. Amount of 6. Ownership 7. Nature																		
Date (Month/I			Date (Month/D	Day/Year) Execution Date, if any (Month/Day/Year)		Code (Ins	str.	Disposed 5) Amount	(A) or (D)		Beneficia Owned F Reported Transact	Beneficially (I		Indirect str. 4)	of Indirect Beneficial Ownership (Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, Transcription Conversion (Month/Day/Year) If any Conversion Co		ansaction of ode (Instr. Derivative			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				c	ode \	v	(A)	(D)	Date Exercisable		piration ate	Title	Amount or Number of Shares					
Restricted Stock Units	(1)	02/03/2023			A		47,500		(2)		(2)	Common Stock	47,500	\$0.00	47,500		D	
Stock Option (Right to Buy)	\$5.5	02/03/2023			A		95,000		(3)	02	2/02/2033	Common Stock	95,000	\$0.00	95,000		D	

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- 2. The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter.
- 3. The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

Remarks:

Executive Vice President and Chief Technology Officer

/s/ Thomas J. DesRosier, attorney-in-fact for David S. Ege

02/07/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.